Abstract 13352: Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-A Modulator, Ameliorated Diabetes-Induced Endothelial Dysfunction

• Published in: Circulation (New York, N.Y.) N.Y.), 2019-11, Vol.140 (Suppl_1 Suppl 1), p.A13352-A13352
• Main Authors: Sutou, Kumiko, Fukuda, Daiju, Ganbaatar, Byambasuren, Yagi, Shusuke, Kusunose, Kenya, Yamada, Hirotsugu, Soeki, Takeshi, Sata, Masataka
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.140.suppl_1.13352

BackgroundAlthough statin therapy suppresses cardiovascular events based on arteriosclerosis, residual risks including hypertriglycemia still remain. Recently, a specific peroxisome proliferator-activated receptor-α modulator (SPPARMα), pemafibrate (K-877), was developed, and presented beneficial effect on lipid control. However, effect of K-877 on vascular function remains unknown. Here, we examined the effects of K-877 on vascular inflammation and endothelial dysfunction in diabetic mice.MethodsDiabetes was induced to seven-week-old male wild-type mice by a single injection of streptozotocin (150 mg/kg). K-877 (0.3 mg/kg/day) was administered orally to diabetic mice fed a normal chow for 3 weeks. The non-treated mice received vehicle. Endothelium-dependent or endothelium-independent vascular response was analyzed by acetylcholine or sodium nitroprusside, respectively, using aortic rings obtained from our mice. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments.ResultsK-877 administration did not affect body weight and cholesterol levels, however it significantly reduced triglyceride level (P